Ophthalmological Management of Patients with Pituitary Adenomas

Sebastian Küchlin; Wolf Alexander Lagrèze

doi:10.1055/a-1291-9383

Klinische Monatsblätter für Augenheilkunde, Table of Contents

Klin Monbl Augenheilkd 2020; 237(11): 1306-1311
DOI: 10.1055/a-1291-9383

Übersicht

Ophthalmologisches Management von Patienten mit Hypophysentumoren

Article in several languages: English | deutsch

Authors

Sebastian Küchlin

Eye Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany
Wolf Alexander Lagrèze

Eye Center, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Germany

Abstract

Zusammenfassung

Hypophysentumoren sind ein häufiger Grund für Funktionseinschränkungen und Degeneration der vorderen Sehbahn. Bei entsprechender Lokalisation und Größe äußern sie sich durch zunächst reversible Gesichtsfelddefekte. Im interdisziplinären Tumormanagement kommt der augenärztlichen Untersuchung bei der Diagnosesicherung, Indikationsstellung zur Tumorresektion und Dokumentation des Therapieerfolges eine besondere Bedeutung zu. Anhand des Verhältnisses zwischen klinischer Dysfunktion und manifester Atrophie, gemeinsam mit dem Patientenalter und der Symptomdauer, kann der Augenarzt Aussagen zur Prognose des postoperativen Sehvermögens treffen. Bei guten Voraussetzungen zeigt sich hier oft bereits früh eine deutliche Gesichtsfeld- und ggf. eine Visusverbesserung. Langzeitkontrollen sind bei persistierender Sehminderung, Strahlentherapie oder Tumorresten mit Nähe zur Sehbahn erforderlich.

Schlüsselwörter

Neuroophthalmologie - Hypophysentumor - Gesichtsfelder - Tumormanagement

Full Text

References

References/Literatur
1 Mehta GU, Lonser RR. Management of hormone-secreting pituitary adenomas. Neuro Oncol 2017; 19: 762-773
2 Vosteen K-H. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF). Unfallchirurgie 1992; 18: 55-56
3 Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA 2017; 317: 516-524
4 Fraser CL, Biousse V, Newman NJ. Visual Outcomes After Treatment of Pituitary Adenomas. Neurosurg Clin N Am 2012; 23: 607-619
5 Molitch ME. Pituitary incidentalomas. Best Pract Res Clin Endocrinol Metab 2009; 23: 667-675
6 Melmed S, Casanueva FF, Hoffman AR. et al. Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2011; 96: 273-288
7 Chanson P, Raverot G, Castinetti F. et al. Management of clinically non-functioning pituitary adenoma. Ann Endocrinol (Paris) 2015; 76: 239-247
8 Wilson P, Falconer MA. Patterns of visual failure with pituitary tumours. Clinical and radiological correlations. Br J Ophthalmol 1968; 52: 94-110
9 Thomas R, Shenoy K, Seshadri MS. et al. Visual field defects in non-functioning pituitary adenomas. Indian J Ophthalmol 2002; 50: 127-130
10 Ogra S, Nichols AD, Stylli S. et al. Visual acuity and pattern of visual field loss at presentation in pituitary adenoma. J Clin Neurosci 2014; 21: 735-740
11 Aghi MK, Chen CC, Fleseriu M. et al. Congress of Neurological Surgeons Systematic Review and Evidence-Based Guidelines on the Management of Patients With Nonfunctioning Pituitary Adenomas: Executive Summary. Neurosurgery 2016; 79: 521-523
12 Abouaf L, Vighetto A, Lebas M. Neuro-ophthalmologic exploration in non-functioning pituitary adenoma. Ann Endocrinol (Paris) 2015; 76: 210-219
13 Monteiro MLR, Zambon BK, Cunha LP. Predictive factors for the development of visual loss in patients with pituitary macroadenomas and for visual recovery after optic pathway decompression. Can J Ophthalmol 2010; 45: 404-408
14 Qiao N, Ye Z, Shou X. et al. Discrepancy between structural and functional visual recovery in patients after trans-sphenoidal pituitary adenoma resection. Clin Neurol Neurosurg 2016; 151: 9-17
15 Esposito D, Olsson DS, Ragnarsson O. et al. Non-functioning pituitary adenomas: indications for pituitary surgery and post-surgical management. Pituitary 2019; 22: 422-434
16 Dekkers OM, de Keizer RJW, Roelfsema F. et al. Progressive improvement of impaired visual acuity during the first year after transsphenoidal surgery for non-functioning pituitary macroadenoma. Pituitary 2007; 10: 61-65
17 Kerrison JB, Lynn MJ, Baer CA. et al. Stages of improvement in visual fields after pituitary tumor resection. Am J Ophthalmol 2000; 130: 813-820
18 Danesh-Meyer HV, Wong A, Papchenko T. et al. Optical coherence tomography predicts visual outcome for pituitary tumors. J Clin Neurosci 2015; 22: 1098-1104
19 Lee J, Kim SW, Kim DW. et al. Predictive model for recovery of visual field after surgery of pituitary adenoma. J Neurooncol 2016; 130: 155-164
20 Moon CH, Hwang SC, Ohn YH. et al. The Time Course of Visual Field Recovery and Changes of Retinal Ganglion Cells after Optic Chiasmal Decompression. Invest Ophthalmol Vis Sci 2011; 52: 7966
21 Gnanalingham KK, Bhattacharjee S, Pennington R. et al. The time course of visual field recovery following transphenoidal surgery for pituitary adenomas: predictive factors for a good outcome. J Neurol Neurosurg Psychiatry 2005; 76: 415-419
22 Guy J, Mancuso A, Beck R. et al. Radiation-induced optic neuropathy: a magnetic resonance imaging study. J Neurosurg 1991; 74: 426-432
23 Zhao Z, Lan Y, Bai S. et al. Late-onset radiation-induced optic neuropathy after radiotherapy for nasopharyngeal carcinoma. J Clin Neurosci 2013; 20: 702-706
24 Murad MH, Fernández-Balsells MM, Barwise A. et al. Outcomes of surgical treatment for nonfunctioning pituitary adenomas: a systematic review and meta-analysis. Clin Endocrinol (Oxf) 2010; 73: 777-791
25 Trautmann JC, Laws ER. Visual Status after Transsphenoidal Surgery at the Mayo Clinic, 1971–1982. Am J Ophthalmol 1983; 96: 200-208
26 Yu FF, Chen LL, Su YH. et al. Factors influencing improvement of visual field after trans-sphenoidal resection of pituitary macroadenomas: a retrospective cohort study. Int J Ophthalmol 2015; 8: 1224-1228
27 Anik I, Anik Y, Koc K. et al. Evaluation of early visual recovery in pituitary macroadenomas after endoscopic endonasal transphenoidal surgery: Quantitative assessment with diffusion tensor imaging (DTI). Acta Neurochir (Wien) 2011; 153: 831-842
28 Lee DK, Sung MS, Park SW. Factors Influencing Visual Field Recovery after Transsphenoidal Resection of a Pituitary Adenoma. Korean J Ophthalmol 2018; 32: 488
29 Luomaranta T, Raappana A, Saarela V. et al. Factors Affecting the Visual Outcome of Pituitary Adenoma Patients Treated with Endoscopic Transsphenoidal Surgery. World Neurosurg 2017; 105: 422-431
30 Muskens IS, Zamanipoor Najafabadi AH, Briceno V. et al. Visual outcomes after endoscopic endonasal pituitary adenoma resection: a systematic review and meta-analysis. Pituitary 2017; 20: 539-552
31 Zaidi HA, Cote DJ, Burke WT. et al. Time Course of Symptomatic Recovery After Endoscopic Transsphenoidal Surgery for Pituitary Adenoma Apoplexy in the Modern Era. World Neurosurg 2016; 96: 434-439
32 Dhasmana R, Nagpal RC, Sharma R. et al. Visual Fields at Presentation and after Trans-sphenoidal Resection of Pituitary Adenomas. J Ophthalmic Vis Res 2011; 6: 187-191
33 Schmalisch K, Milian M, Schimitzek T. et al. Predictors for visual dysfunction in nonfunctioning pituitary adenomas – implications for neurosurgical management. Clin Endocrinol (Oxf) 2012; 77: 728-734
34 Ikeda H, Yoshimoto T. Visual disturbances in patients with pituitary adenoma. Acta Neurol Scand 1995; 92: 157-160
35 Thotakura AK, Patibandla MR, Panigrahi MK. et al. Predictors of visual outcome with transsphenoidal excision of pituitary adenomas having suprasellar extension: a prospective series of 100 cases and brief review of the literature. Asian J Neurosurg 2017; 12: 1
36 Bedrosian JC, McCoul ED, Raithatha R. et al. A prospective study of postoperative symptoms in sinonasal quality-of-life following endoscopic skull-base surgery: dissociations based on specific symptoms. Int Forum Allergy Rhinol 2013; 3: 664-669
37 Sahyouni R, Goshtasbi K, Choi E. et al. Vision Outcomes in Early versus Late Surgical Intervention of Pituitary Apoplexy: Meta-Analysis. World Neurosurg 2019; 127: 52-57
38 Sim FJ, Zhao C, Penderis J. et al. The Age-Related Decrease in CNS Remyelination Efficiency Is Attributable to an Impairment of Both Oligodendrocyte Progenitor Recruitment and Differentiation. J Neurosci 2002; 22: 2451-2459
39 Rajasekaran S, Vanderpump M, Baldeweg S. et al. UK guidelines for the management of pituitary apoplexy. Clin Endocrinol (Oxf) 2011; 74: 9-20
40 Yoneoka Y, Hatase T, Watanabe N. et al. Early morphological recovery of the optic chiasm is associated with excellent visual outcome in patients with compressive chiasmal syndrome caused by pituitary tumors. Neurol Res 2015; 37: 1-8
41 Jacob M, Raverot G, Jouanneau E. et al. Predicting Visual Outcome After Treatment of Pituitary Adenomas With Optical Coherence Tomography. Am J Ophthalmol 2009; 147: 64-70.e2
42 Cohen AR, Cooper PR, Kupersmith MJ. et al. Visual Recovery after Transsphenoidal Removal of Pituitary Adenomas. Neurosurgery 1985; 17: 446-452
43 Barzaghi LR, Medone M, Losa M. et al. Prognostic factors of visual field improvement after trans-sphenoidal approach for pituitary macroadenomas: review of the literature and analysis by quantitative method. Neurosurg Rev 2012; 35: 369-379
44 Lee S, Kim SJ, Yu YS. et al. Prognostic factors for visual recovery after transsphenoidal pituitary adenectomy. Br J Neurosurg 2013; 27: 425-429
45 Ammirati M, Wei L, Ciric I. Short-term outcome of endoscopic versus microscopic pituitary adenoma surgery: a systematic review and meta-analysis. J Neurol Neurosurg Psychiatry 2013; 84: 843-849